LEK formally opens new innovative medicines plant near Ljubljana
Pharmaceutical specialist LEK which is part of the Swiš ss company Novartis has formally opened its new plant at Mengeš near Ljubljana. The plant will produce active substances to be used in innovative medicines in the field of oncology.
The parent company Novartis is launching around €28 million in the plant, the biggest single sum it has invested in any of its Slovene concerns. Previously the biggest investment was the €24 it put into the LEK plant in Lendava in eastern Slovenia. Until now LEK has only been involved in producing generic medicines for Novartis so the development is significant.
LEK is not Slovenia’s only important pharmaceuticals company. Krka employs more than 10,000 people at its base in Novo Mesto which makes generic medicines.